Beximco Pharma starts exports of generics to the US

Beximco Pharmaceuticals, a Bangladeshi manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has begun the export of Carvedilol, a prescription drug for treating hypertension, to the US.

This move follows the product’s approval from the US FDA in November 2015.

It is the first time a pharmaceutical product from Bangladesh has been launched in the US, the firm said.

To mark the delivery of the first consignment on 4 August, and to celebrate this milestone for Beximco Pharma, a brief ceremony was held in the presence of Finance Minister, Abul Maal Abdul Muhith MP; Health and Family Welfare Minister Mohammed Nasim MP and Her Excellency Marcia Stephens Bloom Bernicat, US Ambassador to Bangladesh.

Senior officials from different ministries, including the Export Promotion Bureau (EPB), the Federation of Bangladesh Chambers of Commerce and Industry (FBCCI) and the Bangladesh Association of Pharmaceutical Industries (BAPI) were also in attendance.

Salman F Rahman, Vice Chairman of Beximco Group, said: 'Today is a significant milestone for Beximco Pharma.

'As we deliver our first shipment of Carvedilol to the US market, we begin a new era for the pharmaceutical industry in Bangladesh.

'We believe our continued focus on building and strengthening the Group’s presence in Western markets will cement Bangladesh’s position as a major exporting country.'

Beximco Pharma Managing Director Nazmul Hassan MP, added: 'These initiatives are in line with our aspirations to expand our reach by taking products to the world.

'The US is the largest and most lucrative pharmaceutical market in the world.

'As a leading exporter of medicines, we always strive to capitalise on the generic drug opportunities in the world market.

'We believe our competitive products, especially with specialised and differentiated generic products, will help strengthen our presence in the US and other advanced markets.'

Beximco Pharma became the first Bangladeshi pharmaceutical company to be audited and approved by the US FDA in June 2015.

The company currently has a presence in more than 50 countries and has been accredited by a number of global regulatory authorities, including US FDA, AGES (EU), TGA Australia, Health Canada, GCC and TFDA.